Page 201 - 2021_05-Haematologica-web

ITP associated with MDS and CMML
MDS/CMML-associated SIAD (NCT02985190).
The prognostic significance of MDS-associated SIAD remains controversial.3,4,41-44 In our study, we found no dif- ference in overall survival between MDS/CMML patients with or without ITP. However, leukemia-free survival was significantly better in MDS/CMML patients with ITP than
in MDS/CMML patients without ITP.
Our study has inherent limitations considering its retro-
spective design, but the main limitation is the difficulty in ascertaining the immune origin of thrombocytopenia in MDS/CMML. We believe that our very strict definition of ITP in MDS/CMML patients limited the patients with a predominant central, non-immunological origin of throm- bocytopenia.
In conclusion, patients with MDS/CMML-associated ITP have more severe bleeding than those with primary ITP and have a multirefractory profile, but a lower pro- gression rate toward AML.
Disclosures
GM received research grants form CSL Behring and Novartis for the CARMEN registry in 2016 and 2017-2018. These spon- sors had no role in the data collection and are not the owners of the data; they had no role in the conception, methodology, analyses and interpretation of the studies conducted in the registry and the man- uscript was not submitted to the sponsors before publication. GM also received research grants from Novartis, Grifols, the Institut Servier and meeting attendance grants from Amgen and Novartis.
Contributions
VJ, GM, PF, OF and AM designed the research and analyzed data and then wrote the paper. JH, JS, KL, NS, NV, KS, BG, ODR, RB, JB, NB, TC, CG, OL, LLC, PT, FRP, CS, MV, FI, CS, MV, DG and JEK provided patients’ data, participated in the data analysis and reread the manuscript.
Appendix
MINHEMON: French Network of Dysimmune Disorders Associated with Hemopathies; GFM: Groupe Francophone des Myélodysplasies; CERECAI: Reference Center for Autoimmune CytopeniasinAdults;CARMEN:CytopeńiesAuto-immunes: Registre Midi-Pyreń eÉ N; CARMEN investigators group: Daniel ADOUE, Laurent ALRIC, Sophie ARISTA, Laurent BALARDY, Sarah BETRIAN, Cécile BOREL, Delphine BON- NET, Delphine BRECHEMIER, Miguel CARREIRO, Brice CASTEL, Thibault COMONT, Pierre COUGOUL, Alina DANU, Claire DINGREMONT, Francis GACHES, Marie- Hélène GASPARD, Aurélie GODEL-LABOURET, Patrick GIRAUD, Sondess HADJ-KHELIFA, Benjamin HEBRAUD, Sarah KHATIBI, Lorraine LEPLAY, Yann LEVENEUR, Sylvie OLLIER, Serge MADAULE, Clothilde MARTEL, Guillaume MARTIN-BLONDEL, Martin MICHAUD, Julia MOEGLIN, Philippe MONTANÉ de la ROQUE, Fanny NUCCIO, Maire-Léa PIEL-JULIAN, Laurent PRUDHOMME, Grégory PUGNET, Christian RECHER, Véronique REMY, Laurent SAILLER, Stéphane SIRE, Agnès SOMMET, Suzanne TAVIT- IAN, Willy VAILLANT.
References
1. Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383(9936):2239-2252.
2. Grignano E, Jachiet V, Fenaux P, Ades L, Fain O, Mekinian A. Autoimmune manifes- tations associated with myelodysplastic syndromes. Ann Hematol. 2018;97(11): 2015-2023.
3. Seguier J, Gelsi-Boyer V, Ebbo M, et al. Autoimmune diseases in myelodysplastic syndrome favors patients survival: a case control study and literature review. Autoimmun Rev. 2019;18(1):36-42.
4. Komrokji RS, Kulasekararaj A, Al Ali NH, et al. Autoimmune diseases and myelodys- plastic syndromes. Am J Hematol. 2016;91 (5):E280-283.
5. Ustwani OA, Ford LA, Sait SJN, et al. Myelodysplastic syndromes and autoim- mune diseases - case series and review of literature. Leuk Res. 2013;37(8):894-899.
6. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombo- cytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
7.Hadjadj J, Michel M, Chauveheid M-P, Godeau B, Papo T, Sacre K. Immune throm- bocytopenia in chronic myelomonocytic leukemia. Eur J Haematol. 2014;93(6):521- 526.
8. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neo- plasms and acute leukemia. Blood. 2016;127(20):2391-2405.
9. Pfeilstöcker M, Tuechler H, Sanz G, et al. Time-dependent changes in mortality and
transformation risk in MDS. Blood.
2016;128(7):902-910.
10. Khellaf M, Michel M, Schaeffer A, Bierling
P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoim- mune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica. 2005;90(6):829-832.
11.Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and chil- dren with primary immune thrombocy- topenia: a systematic review. J Thromb Haemost. 2015;13(3):457-464.
12. Mahévas M, Gerfaud-Valentin M, Moulis G, et al. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood. 2016;128(12):1625-1630.
Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune throm- bocytopenia: a nationwide population- based study in France. Blood. 2014;124(22):3308-3315.
18. Braun T, de Botton S, Taksin A-L, et al. Characteristics and outcome of myelodys- plastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leuk Res. 2011;35(7):863-867.
19. Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical evolution of autoimmune cytope- nias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes. Am J Hematol. 2017;92(3):E26-29.
20. Glenthøj A, Ørskov A, Hansen J, Hadrup S, O’Connell C, Grønbæk K. Immune mecha- nisms in myelodysplastic syndrome. Int J Mol Sci. 2016;17(6):944.
21. Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116(22):4639-4645.
22. Bhagat TD, Zhou L, Sokol L, et al. miR-21 mediates hematopoietic suppression in MDS by activating TGF-b signaling. Blood. 2013;121(15):2875-2881.
23. Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strate- gies. Leukemia. 2016;30(3):536-544.
24. Najean Y, Rain JD, Billotey C. The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J Haematol. 1997;97(3):547-550.
25. Sarpatwari A, Provan D, Erqou S, Sobnack
13.
14.
15.
Moulis G, Sailler L, Adoue D, Lapeyre- Mestre M. Pharmacoepidemiology of immune thrombocytopenia: protocols of FAITH and CARMEN studies. Therapie. 2014;69(5):437-448.
Moulis G, Germain J, Comont T, et al. Newly diagnosed immune thrombocytope- nia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol. 2017;92(6):493-500. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419- 425.
16. Bourgeois E, Caulier MT, Rose C, Dupriez B, Bauters F, Fenaux P. Role of splenectomy in the treatment of myelodysplastic syn- dromes with peripheral thrombocytopenia: a report on six cases. Leukemia. 2001;15(6):950-953.
17. Moulis G, Palmaro A, Montastruc J-L,
haematologica | 2021; 106(5)
1421